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Abstract
Background: Histone deacetylase (HDAC) inhibitors are a novel anti-tumor therapy. To determine whether HDAC
inhibitors may be useful in the treatment of adult acute lymphoblastic leukemia (ALL), we examined the
acetylation of histone H4 by immunohistochemistry in newly diagnosed ALL patients and evaluated the impact of
acetylation on complete remission (CR) rate, relapse-free survival (RFS), and overall survival (OS).
Methods: Patients ≥18 years of age and an available diagnostic bone marrow biopsy were evaluated. Cox
proportional hazards analysis was used to identify univariate and multivariate correlates of CR, RFS, and OS. The
variables histone H4 acetylation (positive or negative), white blood count, cytogenetic (CG) risk group (CALGB
criteria), and age were used in multivariate analysis.
Results: On multivariate analysis, histone acetylation was associated with a trend towards an improved OS (for all
CG risk groups) (HR = 0.51, p = 0.09). In patients without poor risk CG, there was an impressive association
between the presence of histone acetylation and an improved CR rate (OR 3.43, p = 0.035), RFS (HR 0.07,
p = 0.005), and OS (HR 0.24, p = 0.007). This association remained statistically significant in multivariate analysis.
Conclusions: These data provide a rationale for the design of novel regimens incorporating HDAC inhibitors in
ALL.
Background
Histones are small basic proteins that complex with
DNA to form nucleosomes [1]. Five types occur in
humans: histone linker H1 and core histones H2A, H2B,
H3, and H4. The core histones are targets for post-
translational modification such as acetylation [1]. His-
tone acetylation is determined by the opposing actions
of histone acetyltransferasesa n dh i s t o n ed e a c e t y l a s e s
(HDACs) [2-4]. Imbalances in histone acetylation can
lead to transcriptional dysregulation of genes involved in
cell cycle progression and/or apoptosis by nucleosome
remodeling. Increased acetylation of histones H3 and
H4 has been associated with transcriptional activation of
several genes involved in the suppression of tumor
growth [1,5,6]. Histone acetylation and expression of
HDACs affect prognosis in a number of cancers. Toh
et al [7] demonstrated a favorable prognosis in patients
with esophageal squamous cell cancer who demon-
strated higher levels of acetylated histone H4. Acetyla-
tion correlated inversely with depth of cancer invasion,
pathologic stage, and expression of the metastasis-asso-
ciated-protein-1. Krusche et al [8] demonstrated that
expression of HDAC-1 was an independent prognostic
marker for patients with breast cancer and correlated
with improved disease-free survival.
HDAC inhibitors represent a novel anti-tumor ther-
apy, and are effective against some T-cell lymphoproli-
ferative disorders. Treatment with HDAC inhibitors in
cutaneous T-cell lymphoma leads to increased histone
acetylation. The cure rate for adults with acute lympho-
blastic leukemia (ALL) remains low, and novel treat-
ment strategies are needed. To determine whether
HDAC inhibitors may be worthwhile evaluating in the
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histone H4 in patients with newly diagnosed ALL and
evaluated the impact of acetylation on complete remis-
sion (CR) rate, relapse-free survival (RFS), and overall
survival (OS). Histone H4 was chosen since we have a
well-validated immunhistochemical stain (see our work
below in the Kasumi cell lines). In addition, histones H4
and H3, in particular, have been associated with tran-
scriptional activation of several genes involved in the
suppression of tumor growth [1,5,6].
Methods
Patients
This research was approved by the Cleveland Clinic
Institutional Review Board. Between 1996 and 2007, all
patients ≥18 years of age with newly diagnosed ALL and
an available diagnostic bone marrow biopsy performed
at the Cleveland Clinic were evaluated. Cytogenetics
were defined according to Cancer and Leukemia Group
B (CALGB) criteria [9]. Poor risk cytogenetics included:
t(9;22), t(4;11), -7, or +8. The remaining cytogenetic
abnormalities were characterized as normal or miscella-
neous (any other abnormality).
Immunohistochemistry
B5-fixed bone marrow core biopsies were reviewed for
areas with the highest concentration of blasts. A tissue
microarray was constructed using 1 mm tissue cores
arrayed in duplicate (Beecher Instruments, Sun Prairie,
WI). Immunohistochemistry was performed using auto-
mated stainers (Ventana Benchmark, Tucson, AZ), and
antibody to acetyl-histone H4 (1:200 dilution; polyclonal;
Upstate Biotech, Lake Placid, NY), which has specificity
for histone H4 acetylated at lysine residues 5, 8, 12, and
16. Heat-induced epitope retrieval was performed using
CC1 solution (Ventana Medical Systems). Five hundred
blasts were counted in each case and only strong
nuclear staining was classified as positive. Based on the
distribution of cell counts, cases were classified as
strongly positive if strong nuclear staining occurred
in ≥40% of the blasts. The 40% was predetermined as
the “definition” of positive before the study was done
based on our previous analyses in acute myeloid leuke-
mia demonstrating a natural clustering of data above
and below 40% (Gibson SE, et al. USCAP Meeting Pos-
ter 151, March 2007). The scoring of each sample was
performed in a blinded fashion. Two investigators
scored the cases, but each case was scored by one inves-
tigator. The level of intensity was not included since the
staining was strong in all patients with >40% nuclear
staining, and weak in patients with ≥40% nuclear stain-
ing. This method of measurement for acetyl-histone H4
was validated in the Kasumi-1 cell line which is derived
from a myeloid leukemia with t(8;21) (q22;q22) and has
been shown to have decreased levels of histone
acetylation.
Cell Culture
Fresh cultured Kasumi-1 cells were cultured in RPMI
1640 medium with 10% fetal bovine serum at 37 degrees
Celsius in a humidified atmosphere containing 5% CO2.
Cells were collected (1 × 10
6 cells/mL) and incubated
with or without the HDAC inhibitor sodium butyrate
(Sigma, St. Louis, MO) for 22 hours. Cells were then
washed once with ice-cold phosphate buffered saline.
Cells for each indicated conditions were divided into
two groups for preparation of both the lysate and cytos-
pin slide. The cells were lysed by incubating with
Laemmli buffer (Bio-Rad, Hercules, CA) for 20 minutes
on ice, followed by heating at 95 degrees Celsius.
Western Blot
The samples were separated by SDS-PAGE in 4-15%
polyacrylamide gel and then transferred onto a polyviny-
lidene membrane (Bio-Rad). Blotting was performed
with 3% bovine serum albumin containing 0.1% Tween
20 (PBST) for 4 hours. The membrane was then incu-
bated with antibody to acetyl-histone H4 overnight at 4
degrees Celsius followed by corresponding secondary
antibody. Detection was performed using enhanced che-
miluminescence reagent (Amersham Pharmacia Biotech,
Piscataway, NJ). The membranes were then stripped and
reprobed with antibody to B-actin (Sigma). For prepara-
tion of cytospin slides, cells of each indicated condition
(5 × 10
5 cells/mL) were centrifuged to glass slides via a
cytofunnel device, followed by fixation in 1% formalin
for 15 minutes. Slides were dried at room temperature
and immunohistochemical staining for acetyl-histone H4
was performed with the same method as used for paraf-
fin-embedded bone marrow samples.
Statistics
Cox proportional hazards analysis was used to identify
univariate and multivariate correlates of CR, OS, and
relapse-free survival (RFS). CR was defined as less than
5% bone marrow blasts, absence of extramedullary leu-
kemia, and recovery of peripheral blood counts (neutro-
phil count >1,000/μL and platelet count >100,000/μL).
T h ef o l l o w i n gv a r i a b l e sw e r eu s e di nu n i v a r i a t ea n d
multivariate analysis: histone H4 acetylation status (posi-
tive or negative), white blood count (≤20,000/uL vs.
>20,000/uL), cytogenetic risk group, and age (≤35 vs.
>35). The latter three variables were chosen since they
have been previously identified as prognostic factors in
ALL [9-11]. Results were summarized as the odds ratio
(OR) or hazard ratio (HR) with 95% confidence intervals
(CI). Patients with unknown cytogenetics were not
included in the multivariate analysis. The Kaplan-Meier
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relapse-free and overall survival. P-values were calcu-
lated according to the log-rank test.
Results
Kasumi Cell Line Results
Untreated Kasumi-1 cells exhibited no staining for
acetyl-histone H4. However, upon incubation with the
HDAC inhibitor sodium butyrate (2 mM or 5 mM), the
Kasumi-1 cells demonstrated increased nuclear staining
for acetyl-histone H4 (Figures 1, 2, 3). Western blot ana-
lysis of these cells, using the same antibody to acetyl-
histone H4 as was used for immunohistochemistry,
showed a similar pattern of increasing acetyl-histone H4
levels with higher concentrations of sodium butyrate
(Figure 4). This demonstrates the specificity of this anti-
body for acetyl-histone H4.
Patient Characteristics
Forty-six patients with ALL treated during this time period
had evaluable bone marrow core biopsies. Patient charac-
teristics are described in (Table 1). The median age was 36
years (range 18-66). The median white blood count was
7800/μL (range 840-278,000) and median LDH 763 U/L
(range 123-4608). 19 patients (41%) had poor risk cytoge-
netics, 11 patients (24% ) normal karyotype, 9 patients
(20%) miscellaneous abnormalities, and 7 patients (15%)
unknown cytogenetics as defined by CALGB criteria.
Forty-two patients (91%) had precursor B-cell ALL, 3
patients (7%) T-cell ALL, and 1 patient (2%) mixed lineage
leukemia. Thirty-four patients (74%) had strong nuclear
expression of acetylated histone H4. Of the T-cell ALL
patients, 2 out of 3 patients (67%) had strong nuclear
expression of acetylated histone H4. (Figures 5 and 6)
illustrate a patient with weak nuclear expression of
acetylated histone H4 (Figure 5) and a patient with strong
nuclear expression of acetylated histone H4 (Figure 6).
There were no associations of age, white blood count at
diagnosis, or cytogenetics with histone acetylation.
Treatment
Most patients (38 patients; 82% of patients) received a
vincristine/prednisone-based induction as described by
the Cancer and Leukemia Group B or the L20 protocol
[12-14]. Five patients (11%) received a high dose cytara-
bine/mitoxantrone regimen [14], and three patients (7%)
received double induction (vincristine/prednisone and
high dose cytarabine/mitoxantrone) on Southwest
Oncology Group protocol S0333. Starting in 2001,
patients with Ph + ALL received imatinib mesylate as
part of their induction and post-remission therapy.
Figure 2 Histone H4 Acetylation by Immunohistochemistry.
Nuclear staining for acetyl-histone H4 in Kasumi-1 cells with 2 mM
of sodium butyrate.
Figure 3 Histone H4 Acetylation by Immunohistochemistry.
Nuclear staining for acetyl-histone H4 in Kasumi-1 cells with 5 mM
of sodium butyrate.
Figure 1 Histone H4 Acetylation by Immunohistochemistry.
Control sample of Kasumi-1 cells with no sodium butyrate.
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plant in first remission.
Response to Therapy and Outcomes
The CR rate after induction therapy was 76%. The med-
ian RFS and median OS were both 21.6 months (from
the time of diagnosis). Patients who underwent trans-
plantation were not censored at the time of transplant.
Prognostic Factors on Univariate and Multivariate
Analysis
Univariate and multivariate analyses for all patients,
including those with poor risk cytogenetics are shown in
Tables 2, 3, 4. Kaplan-Meier graphs of histone H4 acety-
lation and CR, relapse-free survival, and overall survival
are shown in Figures 7 and 8. Histone acetylation was
associated with an improved OS in all patients (HR
0.45; 95% CI 0.21-0.96, p = 0.038) (Table 4). Age at
diagnosis (>35 versus ≤35), white blood count at diagno-
sis (>20,000/μL versus ≤20,000/μL) and cytogenetic risk
group (poor versus others) were associated with a trend
towards a decreased overall survival. However, this was
not statistically significant (Table 4). On multivariate
analysis, histone acetylation was associated with a trend
towards a decreased overall survival (when evaluating all
CG risk groups) (HR 0.51, 95% CI 0.23-1.13, p = 0.09).
However, this was not statistically significant. Treatment
Figure 5 Histone H4 Acetylation in ALL Patient Samples.A
patient with low levels of histone acetylation (Acetyl-histone H4,
original magnification × 400). Olympus BX50 microscope, 100×/1.25
Olympus oil objective, Olympus DP71 camera.
Figure 6 Histone H4 Acetylation in ALL Patient Samples.A
patient with high levels of histone acetylation (Acetyl-histone H4,
original magnification × 400). Olympus BX50 microscope, 100×/1.25
Olympus oil objective, Olympus DP71 camera.
Table 1 Patient characteristics (N = 46 patients)
Patient Characteristics Value Range
Median Age (years) 36 18-66
Median white blood count (/μL) 7,800 840-278,000
Median LDH (U/L) 763 123-4608
Cytogenetic risk groups, n (%)
Poor Risk 19 (41%)
Normal 11 (24%)
Miscellaneous 9 (20%)
Unknown 7 (15%)
Immunophenotype, n (%)
Pre-B 42 (91%)
T-cell 3 (7%)
Mixed Lineage 1 (2%)
Histone Acetylation, n (%)
Present 34 (74%)
Absent 12 (26%)
Figure 4 Histone H4 Acetylation by Western Blotting.F r e s h
cultured Kasumi -1 cells were collected and re-suspended in RPMI
1640 medium with 10% fetal bovine serum in the presence or
absence of indicated doses of sodium butyrate for 22 hours. Cells
were then collected and lysed. Proteins were subjected to SDS-
PAGE and immunoblotted with anti-acetyl-H4. The membrane was
stripped and reprobed with anti-beta actin antibody.
Immunoblotting demonstrated an increasing pattern of histone H4
acetylation with increasing concentrations of sodium butyrate
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prednisone based induction) was not associated with
outcome.
Univariate and multivariate analyses for patients
without poor risk cytogenetics are shown in Tables 5,
6, 7. In patients without poor risk cytogenetics (N =
20), there was an impressive association between his-
tone acetylation and CR rate (OR 3.43, 95% CI 1.09-
10.8, p = 0.035), RFS (HR 0.13, 95% CI 0.03-0.57, p =
0.008), and OS (HR 0.25, CI 0.09-0.69, p = 0.007) on
univariate analysis. This association remained statisti-
cally significant in multivariate analysis when age at
diagnosis, white blood counta td i a g n o s i s ,a n dh i s t o n e
acetylation status were used in the analysis (Tables 5,
6, 7). There was a slight increase in the number of
patients with T-cell ALL (10% of total) in the group
without poor risk cytogenetics. However, the above
results were still valid when evaluating only the B-cell
ALL patients.
Discussion/Conclusions
Histone acetylation was associated with an improved
CR rate, relapse-free survival, and overall survival in
newly diagnosed ALL patients without poor risk cyto-
genetics. These data suggest that histone H4 acetyla-
tion status may help further refine the prognosis of
patients with ALL. Such information may be useful in
risk-stratifying patients. In the 1980s, Hoelzer et al.
defined a prognostic score for ALL patients based on
white blood count, age, immunophenotype, and LDH
[10]. Over the last decade, cytogenetics have become
integral in risk-stratifying patients. Further biological
stratification, using techniques such as histone acetyla-
tion are likely to become important in the future as
we gain a better understanding of the biology of ALL.
The methods for defining histone acetylation in this
study are straightforward and can be performed routi-
nely in most laboratories, making this approach widely
applicable. A more refined prognostic model may be
Table 2 CR Rate: Univariate and Multivariate Analyses for All Patients (N = 46)
Patient Characteristic Odds Ratio (OR) on Univariate Analysis (95%
confidence interval with p-value)
OR on Multivariate Analysis (95% confidence
interval with p-value)
Histone acetylation (Positive
versus negative)
2.24 (0.95-5.28), p = 0.07 2.09 (0.87-5.07), p = 0.10
Age (>35 years vs. ≤35 years) 0.67 (0.32-1.39), p = 0.28 0.77 (0.28-2.12), p = 0.61
White blood count (>20,000/μL
versus ≤20,000/μL)
1.01 (0.47-2.18), p = 0.98 1.18 (0.33-4.26), p = 0.80
Poor risk cytogenetics versus
others
0.89 (0.41-1.90), p = 0.76
Table 3 Relapse-Free Survival: Univariate and Multivariate Analyses for All Patients (N = 46)
Patient Characteristic HR on Univariate Analysis (95% confidence
interval with p-value)
HR on Multivariate Analysis (95% confidence
interval with p-value)
Histone acetylation (Positive versus
negative)
0.42 (0.16-1.13), p = 0.09 0.55 (0.19-1.59), p = 0.27
Age (>35 years vs. ≤35 years) 1.81 (0.75-4.34), p = 0.19 1.39 (0.35-5.72), p =0 .65
White blood count (>20,000/μL
versus ≤20,000/μL)
3.88 (1.54-9.79), p = 0.004 15.0 (2.41-89.5), p = 0.003
Poor risk cytogenetics versus others 2.36 (0.93-6.03), p = 0.07
Table 4 Overall Survival: Univariate and Multivariate Analyses for All Patients (N = 46)
Patient Characteristic HR on Univariate Analysis (95% confidence
interval with p-value)
HR on Multivariate Analysis (95% confidence
interval with p-value)
Histone acetylation (Positive versus
negative
0.45 (0.21-0.96), p = 0.038 0.51 (0.23-1.31), p = 0.09
Age (>35 years vs. ≤35 years) 1.81 (0.84-3.91), p = 0.13 2.41 (0.75-7.74), p = 0.14
White blood count (>20,000/μL
versus ≤20,000/μL)
1.87 (0.87-4.03), = 0.11 3.36 (0.90-12.5), p = 0.07
Poor risk CG vs. others 1.95 (0.82-4.68), p = 0.13
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terns, as was done by Seligson et al. in prostate cancer
[15]. They evaluated the percent of cells that stained
for the histone acetylation and dimethylation of five
residues in histones H3 and H4. Although this may
lead to a more refined risk score, the methods are
more labor intensive. Finally, it is unclear if histone
acetylation per se is associated with disease prognosis
or if this is a marker for the biological activity of the
tumor cells.
Histone acetylation was a prognostic factor on uni-
variate analysis, but not multivariate analysis when
including patients with poor risk cytogenetics.
Although this may be secondary to inherent differ-
ences in the biology (other genetic or epigenetic
changes) of the poor risk patients, it is also possible
that allogeneic bone marrow transplant abrogated the
prognostic impact of histone acetylation in these
patients since a majority of patients with poor risk
cytogenetics underwent transplant in first remission.
There was no significant difference in histone acetyla-
tion in patients with poor risk cytogenetics versus
other cytogenetic groups.
T h el i m i t a t i o n so ft h i ss t u d ya r et h es a m p l es i z e ,h e t -
erogeneity of treatment, and the increased number of
patients with poor risk cytogenetics. Age, cytogenetics,
and white blood count at diagnosis were not significant
prognostic factors due to the small sample size. How-
ever, there was a trend towards these being prognostic
factors. In addition, we took these factors into account
in the multivariate analysis. Despite the small sample
size, histone acetylation was a significant prognostic
factor for patients with normal and miscellaneous
cytogenetic abnormalities on both univariate and
Figure 7 Kaplan-Meier curves of histone acetylation and
relapse-free survival (RFS).
Figure 8 Kaplan-Meier curves of histone acetylation and
overall survival.
Table 6 Relapse-Free Survival: Univariate and Multivariate Analysis in Patients without Poor Risk Cytogenetics
(N = 20)
Patient Characteristic HR on Univariate Analysis (95% confidence
interval with p-value)
HR on Multivariate Analysis (95% confidence
interval with p-value)
Histone acetylation (Positive versus
negative)
0.13 (0.03-0.57), p = 0.008 0.07 (0.01-0.44), p = 0.005
Age (>35 years vs. ≤35 years) 1.95 (0.59-6.50), p = 0.28 1.56 (0.40-6.07), p = 0.53
White blood count (>20,000/μL
versus ≤20,000/μL)
1.11 (0.32-3.92), p = 0.87 14.9 (2.55-87.6), p = 0.003
Table 5 CR Rate: Univariate and Multivariate Analysis in Patients without Poor Risk Cytogenetics (N = 20)
Patient Characteristic Odds Ratio (OR) on Univariate Analysis (95%
confidence interval with p-value)
OR on Multivariate Analysis (95% confidence
interval with p-value)
Histone acetylation (Positive
versus negative)
3.43 (1.09-10.8), p = 0.035 3.22 (0.98-10.6), p = 0.053
Age (>35 years vs. ≤35 years) 0.61 (0.23-1.58), p = 0.31 0.82 (0.30-2.21), p = 0.82
White blood count (>20,000/μL
versus ≤20,000/μL)
1.11 (0.32-3.92), p = 0.87 1.06 (0.30-3.79), p = 0.93
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firmed in an independent data set with a large number
of patients treated on a uniform protocol. Evaluating
other histones, such as histone H3, will also be
important.
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